Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0038362 (
stomatitis
)
8,852
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
It has been assumed that R5 and X4 HIV utilize similar strategies to support viral cDNA synthesis post viral entry. In this study, we provide evidence to show that R5 and X4 HIV have distinct requirements for host cell uracil DNA glycosylase (
UNG2
) during the early stage of infection.
UNG2
has been previously implicated in HIV infection, but its precise role remains controversial. In this study we show that, although
UNG2
is highly expressed in different cell lines,
UNG2
levels are low in the natural host cells of HIV. Short interfering RNA knockdown of endogenous
UNG2
in primary cells showed that
UNG2
is required for R5 but not X4 HIV infection and that this requirement is bypassed when HIV enters the target cell via vesicular
stomatitis
virus envelope-glycoprotein-mediated endocytosis. We also show that short interfering RNA knockdown of
UNG2
in virus-producing primary cells leads to defective R5 HIV virions that are unable to complete viral cDNA synthesis. Quantitative PCR analysis revealed that endogenous
UNG2
levels are transiently up-regulated post HIV infection, and this increase in
UNG2
mRNA is approximately 10-20 times higher in R5 versus X4 HIV-infected cells. Our data show that both virion-associated
UNG2
and HIV infection-induced
UNG2
expression are critical for reverse transcription during R5 but not X4 HIV infection. More importantly, we have made the novel observation that R5 and X4 HIV have distinct host cell factor requirements and differential capacities to induce gene expression during the early stages of infection. These differences may result from activation of distinct signaling cascades and/or infection of divergent T-lymphocyte subpopulations.
...
PMID:X4 and R5 HIV-1 have distinct post-entry requirements for uracil DNA glycosylase during infection of primary cells. 2037 2